Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2006-05-30
2006-05-30
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S185100, C424S186100, C424S188100, C424S208100, C530S324000, C530S350000, C530S826000
Reexamination Certificate
active
07052699
ABSTRACT:
The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine.
REFERENCES:
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5030449 (1991-07-01), Berzofsky et al.
patent: 5081226 (1992-01-01), Berzofsky et al.
patent: 5336758 (1994-08-01), Berzofsky et al.
patent: 5352576 (1994-10-01), Haynes et al.
patent: 5516632 (1996-05-01), Palker et al.
patent: 5622703 (1997-04-01), Berzofsky et al.
patent: 5695762 (1997-12-01), Berzofsky et al.
patent: 5711947 (1998-01-01), Berzofsky et al.
patent: 5820865 (1998-10-01), Berzofsky et al.
patent: 5853978 (1998-12-01), Berman et al.
patent: 5864027 (1999-01-01), Berman
patent: 5882853 (1999-03-01), Berzofsky et al.
patent: 5932218 (1999-08-01), Berzofsky et al.
patent: 5939074 (1999-08-01), Berzofsky et al.
patent: 5976541 (1999-11-01), Berzofsky et al.
patent: 5976551 (1999-11-01), Mottez et al.
patent: 5980899 (1999-11-01), Berzofsky et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 5997869 (1999-12-01), Goletz et al.
patent: 6042836 (2000-03-01), Berman et al.
patent: 6214347 (2001-04-01), Berzofsky et al.
patent: 6290963 (2001-09-01), Fischinger et al.
patent: 6294322 (2001-09-01), Berzofsky et al.
patent: 6458527 (2002-10-01), Luciw et al.
patent: 6592872 (2003-07-01), Klimpel et al.
patent: 6656471 (2003-12-01), Sastry et al.
patent: 2001/0036461 (2001-11-01), Haynes et al.
patent: 2003/0147888 (2003-08-01), Haynes et al.
patent: 2004/0039172 (2004-02-01), Haynes et al.
patent: 2002/0086283 (2004-02-01), Haynes et al.
patent: 2004/0132010 (2004-07-01), Haynes et al.
patent: 0 693 938 (1996-01-01), None
patent: WO 91/04051 (1991-04-01), None
patent: WO 93/04697 (1993-03-01), None
patent: WO 93/15750 (1993-08-01), None
patent: WO 94/26785 (1994-11-01), None
patent: WO 94/28929 (1994-12-01), None
patent: WO 94/29339 (1994-12-01), None
patent: WO 95/29700 (1995-11-01), None
patent: WO 96/41189 (1996-12-01), None
patent: WO 97/14436 (1997-04-01), None
patent: WO 98/01564 (1998-01-01), None
patent: WO 00/52040 (2000-09-01), None
patent: WO 01/43693 (2001-06-01), None
patent: WO 01/54719 (2001-08-01), None
patent: WO 01/56355 (2001-08-01), None
patent: WO 02/08716 (2002-01-01), None
patent: WO 02/20555 (2002-03-01), None
patent: WO 02/024149 (2002-03-01), None
patent: WO 2002/20554 (2002-03-01), None
patent: WO 02/069691 (2002-09-01), None
patent: WO 03/039470 (2003-05-01), None
patent: WO 03/046137 (2003-06-01), None
patent: WO 2004/009785 (2004-01-01), None
patent: WO 2004/075850 (2004-09-01), None
patent: WO 2005/016952 (2005-02-01), None
patent: WO 2005/028625 (2005-03-01), None
Sheppard et al, “The characterization of non-progressors: long-term HIV-1 infection will stable CD4+ T-cell levels”, AIDS 7:1159-1166 (1993).
Phair, John P., Keynote Address: “Variations in the Natural History of HIV Infection”,AIDS Research and Human Retroviruses10(8):883 885 (1994).
Pantaleo et al, “Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection”, N. Engl. J. Med. 332(4):209-216 (1995).
Cao et al, “Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection”, N. Engl. J. Med. 332(4):201-208 (1995).
Pantaleo et al, “Major expansion of CD8+ T cells with a predominant Vβ usage during the primary Immune response to HIV”, Nature 3970:463-467 (1994).
Mellors et al, “Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion”, Ann. Intern. Med. 122:573-579 (1995).
Jurriaans et al, “The Natural History of HIV-1 Infection: Virus Load and Virus Phenotype Independent Determinants of Clinical Course?”, Virology 204:223-233 (1994).
Borrow et al, “Virus-Specific CD8+ Cytotoxic T-Lymphoctye Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection”, Journal of Virology 68(9):6103-6110 (1994).
Haynes et al, “Toward an Understanding of the Correlates of Protective Immunity to HIV Infection”, Science 271:324-328 (1996).
Haynes, Barton F., “Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development”, Science 260:1279-1286 (1993).
Nowak et al, “Antigenic oscillations and shifting Immunodominance in HIV-1 Infections”, Nature 375:606-611 (1995).
Walker et al, “CD8+ Lymphocytes Can Control HIV Infection in Vitro by Suppressing Virus Replication”, Science 234:1563-1566 (1986).
Baler et al, “HIV suppression by interleukin-16”, Nature 378:563 (1995).
Cocchi et al, “Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells”, Science 270:1811-1815 (1995).
Feng et al, “HIV-1 Entry Cofactor Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor”, Science 272:872-877 (1996).
Wei et al, “Viral dynamics in human immunodeficiency virus type 1 infection”, 373:117-122 (1995).
Palker et al, “Polyvalent Human Immunodeficiency Virus Synthetic Immunogen Comprised of Envelope gp120 T Helper Cell Sites and B Cell Neutralization Epitopes”, The Journal of Immunology 142:3612-3619 (1989).
Berzofsky, Jay A., “Development of artificial vaccines against HIV using defined epitopes”, The FASEB Journal 5:2412-2418 (1991).
Haynes et al, “HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3 Peptides as a Polyvalent Immunogen”, AIDS Research and Human Retroviruses 11(2):211-221 (1995).
Williams and McAuley, “HLA Class I Variation Controlled for Genetic Admixture in the Gila River Indian Community of Arizona: A Model for the Paleo-Indians”, Human Immunology 33:39-46 (1992).
Hardy, G.H., “Mendelian Proportions in a Mixed Population”, Science, N.S. XXVIII, (706):49-50 (1908).
Schneider et al, “Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara”, Nature Medicine 4:397-402 (1998).
Ferrari et al, “Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers”, Proc. Natl. Acad. Sci. USA 94:1396-1401 (1997).
Cease and Berzofsky, “Toward A Vaccine For AIDS: The Emergence of Immunobiology-Based Vaccine Development”, Annu. Rev. Immunol. 12:923-989 (1994).
Guleria et al, “Auxotrophic vaccines for tuberculosis”, Nature Medicine 2(3):334-337 (1996).
Beddows et al, “Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies”, Journal of General Virology 79:77-82 (1998).
Sullivan et al, “Replicative Function and Neutralization Sensitivity of Envelope Glycoproteins from Primary and T-Cell Line-Passaged Human Immunodeficiency Virus Type 1 Isolates”, Journal of Virology 69(7):4413-4422 (1995).
Rowland-Jones et al, HIV-Specific Cytotoxic T-Cells in HIV-Exposed but Uninfected Gambian Women, Nat. Med. 1(1):59-64 (1995) (Abstract) complete ref. next page.
Lee et al, “Circulating HIV-1-Infectd Cell Burden From Seroconversion to AIDS: Importance of Postseroconversion Viral Load on Disease Course”, Journal of Acquired Immune Deficiency Syndromes 7:381-388 (1994).
Rowland-Jones et al, “HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women”, Nature Medicine 1(1):59-64 (1995).
Wain-Hobson et al, Simon in the Evolutionary biology of viruses, Stephen S. Morse (ed), Raven Press, NY, pp. 185-209 (1994)—Abstract.
Ho et al, “Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection”, Nature 373:123-126 (1995).
Robertson et al, “Recombination in AIDS Viruses”, Journal of Molecular Evolution 40:249-259 (1995).
Haynes et al, “Use
Haynes Barton F.
Letvin Norman
Liao Hua-Xin
Beth Israel Deaconess Medical Center
Duke University
Nixon & Vanderhye P.C.
Stucker Jeffrey
LandOfFree
Immunogenic composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3536143